Skip to main content
Evidence: C+Skin & HairSexual Health

Melanotan II: Benefits, Dosage & FDA Status

Melanotan II (MT-II)

A non-selective melanocortin agonist (MC1R/MC3R/MC4R) that produces tanning and erection effects. Significant safety concerns including melanoma case reports.

FDA Status

Not FDA-approved — sold illegally as cosmetic; FDA warning letters issued

Typical Dose

0.25–1 mg daily during loading, then maintenance (subcutaneous)

Evidence Grade

C+Preclinical evidence + anecdotal clinical use

Half-Life

~2 hours

Routes of Administration

subcutaneous

First Synthesized

1980s

Clinics Indexed

18 providers have offered Melanotan II in our tracked directory.

Mechanism of Action

Cyclic synthetic α-MSH analog activating MC1R (pigmentation) and MC3R/MC4R (CNS effects on libido and appetite).

Key Reported Benefits

Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C+ indicates preclinical evidence + anecdotal clinical use.

Reported Side Effects

  • Nausea
  • Flushing
  • New mole formation
  • Reported melanoma cases

Contraindications

  • Personal/family history of melanoma
  • Atypical mole syndrome
  • Pregnancy

Regulatory & Safety Context

FDA status: Not FDA-approved — sold illegally as cosmetic; FDA warning letters issued

This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.

See state-by-state legality: US peptide legality by state →

References

Selected primary literature on Melanotan II. Full PubMed records linked. Additional citations are available on request.

  1. PubMed PMID 19650849

Last reviewed: 2026-04-30

← Back to all peptides